MarkJRatainMD

PubMed

• Critical importance of correctly defining and reporting secondary endpoints when assessing the ethics of research biopsies.
  Laura A Levit, Elizabeth Garrett-Mayer, Jeffrey Peppercorn, Mark J Ratain> ;Clinical Trials. 2024 Apr 23
• Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer.
  Mark J Ratain> ;Clinical Pharmacology and Therapeutics. 2024 Apr 11
• Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance).
  Jai N Patel, Chen Jiang, Kouros Owzar, Daniel L Hertz, Janey Wang, Flora A Mulkey, William K Kelly, Susan Halabi, Yoichi Furukawa, Cameron Lassiter, Susan G Dorsey, Pa...> ;The Pharmacogenomics Journal. 2024 Mar 4
• Sotorasib dosing and incremental cost ineffectiveness - implications and lessons for stakeholders.
  Garth W Strohbehn, Mark J Ratain> ;Nature Reviews. Clinical Oncology. 2024 May 1
• Optimizing the doses of cancer drugs after usual dose finding.
  Strohbehn, G., Boonstra, P., Stadler, W., Ratain, M.> ;Clinical Trials. 2023 Dec 27
• Special designations and the US Food and Drug Administration's "dual mandate".
  Strohbehn, G., Ratain, M.> ;Journal of the National Cancer Institute. 2024 Feb 8
• An Ethical and Financial Obligation for Sickle Cell Disease Gene Therapy in the United States.
  Wesevich, A., Peek, M., Ratain, M.> ;Annals of Internal Medicine. 2024 Jan 1
• Common variation in a long non-coding RNA gene modulates variation of circulating TGF-2 levels in metastatic colorectal cancer patients (Alliance).
  Quintanilha, J., Sibley, A., Liu, Y., Niedzwiecki, D., Halabi, S., Rogers, L., O'Neil, B., McLeod, H., Nixon, A., Innocenti, F., Owzar, K., Kindler, H., Kelly, W., Ven...> ;Medrxiv. 2023 Dec 4
• Do patent applications and Cooperative Research and Development Agreements between the National Cancer Institute and industry serve the public interest?
  Austin Wesevich, Mark J Ratain> ;Nature Biotechnology. 2023 Nov 1
• Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?
  Mark J Ratain, Garth W Strohbehn> ;European Journal of Cancer. 2023 Nov 1
• Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?
  Austin Wesevich, Mark J Ratain> ;JAMA Oncology. 2023 Nov 1
• 3 citations
  Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies.
  Austin Wesevich, Daniel A Goldstein, Koosha Paydary, Cody J Peer, William D Figg, Mark J Ratain> ;British Journal of Cancer. 2023 Oct 1
• Alternative Trastuzumab Dosing Schedules Are Associated With Reductions in Health Care Greenhouse Gas Emissions.
  Sofia I Jacobson, Alec J Kacew, Randall W Knoebel, Po-Hung Hsieh, Mark J Ratain, Garth W Strohbehn> ;JCO Oncology Practice. 2023 Sep 1
• 1 citations
  Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy.
  I F Tannock, G Bouche, D A Goldstein, Y Goto, A S Lichter, K Prabhash, P Ranganathan, L B Saltz, G S Sonke, G W Strohbehn, R von Moos, M J Ratain> ;Annals of Oncology. 2023 Aug 1
• 4 citations
  US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?
  Garth W Strohbehn, Allen S Lichter, Mark J Ratain> ;Journal of Clinical Oncology. 2023 May 10
• 4 citations
  In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation.
  Cody J Peer, Keith T Schmidt, Oluwatobi Arisa, William J Richardson, Koosha Paydary, Daniel A Goldstein, James L Gulley, William D Figg, Mark J Ratain> ;Journal of Clinical Pharmacology. 2023 Jun 1
• 2 citations
  Implementation of pharmacogenomics into inpatient general medicine.
  Thomas Chen, Peter H O'Donnell, Merisa Middlestadt, Gregory W Ruhnke, Keith Danahey, Xander M R van Wijk, Anish Choksi, Randall Knoebel, Seth Hartman, Kiang-Teck Jerry...> ;Pharmacogenetics and Genomics. 2023 Feb 1
• 17 citations
  Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
  D Araujo, A Greystoke, S Bates, A Bayle, E Calvo, L Castelo-Branco, J de Bono, A Drilon, E Garralda, P Ivy, O Kholmanskikh, I Melero, G Pentheroudakis, J Petrie, R Plu...> ;Annals of Oncology. 2023 Jan 1
• An Expanded Role for IRBs in the Oversight of Research Biopsies.
  Laura A Levit, Julie Kaneshiro, Jeffrey Peppercorn, Mark J Ratain> ;Ethics & Human Research. 2022 Sep 1
• 5 citations
  Drug Interactions With a Short Course of Nirmatrelvir and Ritonavir: Prescribers and Patients Beware.
  Mark J Ratain, David J Greenblatt> ;Journal of Clinical Pharmacology. 2022 Aug 1
• 7 citations
  Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.
  Patricia LoRusso, Mark J Ratain, Toshihiko Doi, Drew W Rasco, Maja J A de Jonge, Victor Moreno, Benedito A Carneiro, Lot A Devriese, Adam Petrich, Dimple Modi, Susan M...> ;Investigational New Drugs. 2022 Aug 1
• 2 citations
  Oncology Drug Prescribing: The Influences of Greed and Fear.
  Mark J Ratain> ;JCO Oncology Practice. 2022 Sep 1
• 1 citations
  The dosing of ibrutinib and related Bruton's tyrosine kinase inhibitors: eliminating the use of brute force.
  Mark J Ratain, Ian F Tannock, Allen S Lichter> ;Blood Advances. 2022 Sep 13
• 1 citations
  Two polymorphic gene loci associated with treprostinil dose in pulmonary arterial hypertension.
  Vasiliki Thomeas-McEwing, Mitchell A Psotka, Eric R Gamazon, Paula Friedman, Anuar Konkashbaev, Michiaki Kubo, Yusuke Nakamura, Mark J Ratain, Raymond L Benza, Nancy J...> ;Pharmacogenetics and Genomics. 2022 Jun 1
• 2 citations
  Lorlatinib Exposed: A Far From Optimal Dose.
  Garth W Strohbehn, Mark J Ratain> ;Clinical Pharmacology and Therapeutics. 2022 Jun 1
• Join now to see all

Journal Articles

• Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19  
  Mark J Ratain, Leonard B Saltz, JAMA Oncology
• A Pharmacogenetic Prediction Model of Progression‐Free Survival in Breast Cancer Using Genome‐Wide Genotyping Data from CALGB 40502 (Alliance)  
  Hope S Rugo, Francisco Castillos, Beth Overmoyer, Mark J Ratain, Clinical Pharmacology & Therapeutics
• A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469  
  Ramirez J, Kim TW, Liu W, Myers JL, Mirkov S, Owzar K, Watson D, Mulkey F, Gamazon ER, Stock W, Undevia S, Innocenti F, Ratain MJ, Pharmacogenet Genomics, 1/1/2014
• Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs  
  Wu K, House L, Ramirez J, Seminerio MJ, Ratain MJ, Clin Cancer Res, 1/1/2013
• Germline variants and advanced colorectal adenomas: Adenoma Prevention with Celecoxib Prevention Trial genomewide association study  
  Wang J, Carvajal-Carmona LG, Chu JH, Zauber AG, Collaborators AT, Kubo M, Matsuda K, Dunlop M, Houlston RS, Sieber OM, Lipton L, Gibbs P, Martin NG, Montgomery GW, You..., Clin Cancer Res, 1/1/2013
• Preventing adverse drug-drug interactions: a need for improved data and logistics  
  Seminerio MJ, Ratain MJ, Mayo Clin Proc, 1/1/2013
• Time to tumor growth: a model endpoint and new metric system for oncology clinical trials  
  Maitland ML, Schwartz LH, Ratain MJ, J Clin Oncol, 1/1/2013
• CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality  
  Ratain MJ, Nakamura Y, Cox NJ, Clin Pharmacol Ther, 1/1/2013
• Are drug labels static or dynamic?  
  Seminerio MJ, Ratain MJ, Clin Pharmacol Ther, 1/1/2013
• Tumour heterogeneity in the clinic  
  Bedard PL, Hansen AR, Ratain MJ, Siu LL, Nature, 1/1/2013
• University of Chicago Center for Personalized Therapeutics: research, education and implementation science  
  Dolan ME, Maitland ML, O’Donnell PH, Nakamura Y, Cox NJ, Ratain MJ, Pharmacogenomics, 1/1/2013
• Challenges in interpreting the evidence for genetic predictors of ototoxicity  
  Ratain MJ, Cox NJ, Henderson TO, Clin Pharmacol Ther, 1/1/2013
• Unmet needs in preventing adverse drug-drug interactions  
  Ratain MJ, Seminerio MJ, Clin Adv Hematol Oncol, 1/1/2013
• The relationship of polymorphisms in ABCC2 and SLCO1B3 to docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance)  
  Lewis LD, Miller AA, Owzar K, Bies RR, Markova S, Jiang C, Kroetz DL, Egorin MJ, McLeod HL, Ratain MJ, Pharmacogenet Genomics, 1/1/2013
• Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of paclitaxel-induced sensory neuropathy  
  Wheeler HE, Gamazon ER, Wing C, Njaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I, Kubo M, Zembutsu H, Winer EP, Hudis CA, Shulman L, Ratain MJ, Kro..., Clin Cancer Res, 1/1/2013
• Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression  
  Nguyen TD, Markova S, Liu W, Gow JM, Baldwin RM, Habashian M, Relling MV, Ratain MJ, Kroetz DL, Pharmacogenomics, 1/1/2013
• Estimation of renal cell carcinoma treatment effects from disease progression modeling  
  Maitland ML, Wu K, Sharma MR, Jin Y, Kang SP, Stadler WM, Karrison TG, Ratain MJ, Bies RR, Pharmacol Ther, 1/1/2013
• Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients  
  Wang LZ, Ramírez J, Yeo W, Chan MY, Thuya WL, Lau JY, Wan SC, Wong AL, Zee YK, Lim R, Lee SC, Ho PC, Lee HS, Chan A, Ansher S, Ratain MJ, Goh BC, PLoS ONE, 1/1/2013
• Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients  
  Sharma MR, Karrison TG, Kell B, Wu K, Turcich M, Geary D, Kang SP, Takebe N, Graham RA, Maitland ML, Schilsky RL, Ratain MJ, Cohen EE, Clin Cancer Res, 1/1/2013
• Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751  
  Innocenti F, Ramírez J, Obel J, Xiong J, Mirkov S, Chiu YL, Katz DA, Carr RA, Zhang W, Das S, Adjei A, Moyer AM, Chen PX, Krivoshik A, Medina D, Gordon GB, Ratain MJ, ..., Pharmacogenet Genomics, 1/1/2013
• A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection  
  Kitano S, Myers J, Nakamura J, Yamane A, Yamashita M, Nakayama M, Tsukahara Y, Ushida H, Liu W, Ratain MJ, Amano M, PLoS ONE, 1/1/2013
• A genome-wide integrative study of microRNAs in liver  
  Gamazon ER, Innocenti F, Wei R, Wang L, Zhang M, Mirkov S, Ramirez J, Huang RS, Cox NJ, Ratain MJ, Liu W, BMC Genomics, 1/1/2013
• Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis  
  Bhatta SS, Wroblewski KE, Agarwal KL, Sit L, Cohen EEW, Seiwert TY, Karrison T, Bakris GL, Ratain MJ, Vokes EE, Maitland ML, Oncologist, 1/1/2013
• Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter OCT1 via binding to an evolutionary conserved region in intron 1 of the OCT1 gene  
  O’Brien VP, Bokelmann K, Ramirez J, Jobst K, Ratain MJ, Brockmoller J, Tzvetkov MV, J Pharmacol Exp Ther, 1/1/2013
• Reply to M Todd et al (Letter)  
  Ratain MJ, J Clin Oncol, 1/1/2012
• Join now to see all

Lectures

• Phase 1, first-in-human study of TRAIL receptor agonist fusion protein ABBV-621. 
  2019 ASCO Annual Meeting - 6/1/2019